157 related articles for article (PubMed ID: 21254877)
1. Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U; Scheulen ME; von Bergwelt-Baildon MS; Weihrauch MR
Expert Opin Investig Drugs; 2011 Mar; 20(3):361-72. PubMed ID: 21254877
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.
Krieg AM
Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597
[TBL] [Abstract][Full Text] [Related]
4. TLR9 in health and disease.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):155-81. PubMed ID: 16818370
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
6. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
Rayburn ER; Wang W; Zhang R; Wang H
Int J Oncol; 2007 Jun; 30(6):1511-9. PubMed ID: 17487373
[TBL] [Abstract][Full Text] [Related]
7. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
Jurk M; Vollmer J
BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
11. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
Mutwiri G
Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
[TBL] [Abstract][Full Text] [Related]
12. [Cancer immunotherapy with CpG-ODN].
Carpentier AF
Med Sci (Paris); 2005 Jan; 21(1):73-7. PubMed ID: 15639024
[TBL] [Abstract][Full Text] [Related]
13. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
14. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
Putta MR; Yu D; Bhagat L; Wang D; Zhu FG; Kandimalla ER
J Med Chem; 2010 May; 53(9):3730-8. PubMed ID: 20361743
[TBL] [Abstract][Full Text] [Related]
15. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
Murad YM; Clay TM
BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.
Vicari AP; Luu R; Zhang N; Patel S; Makinen SR; Hanson DC; Weeratna RD; Krieg AM
Cancer Immunol Immunother; 2009 Apr; 58(4):615-28. PubMed ID: 18802696
[TBL] [Abstract][Full Text] [Related]
18. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.
Hirsch I; Caux C; Hasan U; Bendriss-Vermare N; Olive D
Trends Immunol; 2010 Oct; 31(10):391-7. PubMed ID: 20832362
[TBL] [Abstract][Full Text] [Related]
19. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
20. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
Najar HM; Dutz JP
Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
